An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920
Status:
Completed
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US.
It is designed to assess systemic exposure to articaine and its metabolite articainic acid
after dosing a single topical ocular administration of AG-920 in the randomized study eye.